Post-earnings recap
Reported
Tue, Mar 9, 2010
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ACADIA Pharmaceuticals reported a loss per share that was worse than expected, but the stock still rose by 3.68%. This increase may be due to investors focusing on other positive aspects of the company's outlook or market conditions. Without additional commentary from management, it's difficult to assess the reasons behind the stock's positive reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -21.05% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.